SHR-A1811 for Subjects With Her2-positive Gastric Cancer and Gastroesophageal Junction Adenocarcinoma After Progression on or After First-line Anti-HER2 Therapy-containing Regimen
A phase 3 trial of Trastuzumab rezetecan, Docetaxel and Ramucirumab in gastric & gastro-oesophageal junction cancer, run by Jiangsu HengRui Medicine Co., Ltd., now recruiting.
Overview
SHR-A1811 for Subjects With Her2-positive Gastric Cancer and Gastroesophageal Junction Adenocarcinoma After Progression on or After First-line Anti-HER2 Therapy-containing Regimen is a phase 3 interventional study registered as NCT06123494 by Jiangsu HengRui Medicine Co., Ltd., with 360 participants planned, started 2024-01-09 and due to reach its primary completion in 2027-06-30. Interventions recorded: SHR-A1811 and Ramucirumab / Paclitaxel/ Docetaxel/ Irinotecan.
Similar pages
not linked directly; found by shared links- TrialSafety and Efficacy of SHR2554 Combined With Other Antitumor Therapies in Gastric or Gastro-oesophageal Junction Adenocarcinoma
Shares Trastuzumab rezetecan, Jiangsu Hengrui Pharmaceuticals, Gastric & gastro-oesophageal junction cancer and the tag pipeline.
- TrialA Phase III Study of SHR-A1811 Injection With or Without Pertuzumab in HER2-Positive Recurrent or Metastatic Breast Cancer
Shares Trastuzumab rezetecan, Docetaxel, Jiangsu Hengrui Pharmaceuticals and the tag pipeline.
- TrialA Trial of Adebrelimab Plus (SHR-A1811/SHR-A1904 With Chemotherapy) or SHR-8068 as Treatment for Gastric/GEJ Cancer
Shares Trastuzumab rezetecan, Jiangsu Hengrui Pharmaceuticals, Gastric & gastro-oesophageal junction cancer and the tag pipeline.
- TrialA Study of SHR-4610 Injection in Patients With Advanced Solid Tumors
Shares Trastuzumab rezetecan, Jiangsu Hengrui Pharmaceuticals and the tag pipeline.
- TrialPhase II Clinical Study of SHR-A1811 in Patients With HER2 Expression / Amplification of Locally Advanced Unresectable or Recurrent Metastatic Biliary Tract Cancer
Shares Trastuzumab rezetecan, Jiangsu Hengrui Pharmaceuticals and the tag pipeline.
- TrialA Phase III, Active-Controlled Study of SHR-A1811 Versus Trastuzumab Emtansine (T-DM1) in HER2-Positive Primary Breast Cancer Participants With Residual Invasive Disease Following Neoadjuvant Therapy
Shares Trastuzumab rezetecan, Jiangsu Hengrui Pharmaceuticals and the tag pipeline.
- TrialA Trial of SHR-A1811 Combined With Other Antitumor Therapies in Advanced Solid Tumors.
Shares Trastuzumab rezetecan, Jiangsu Hengrui Pharmaceuticals and the tag pipeline.
- TrialPh1b/2 Study of the Safety and Efficacy of SHR-A1811 Combinations in Advanced HER2 Expression Gastric Cancer
Shares Trastuzumab rezetecan, Jiangsu Hengrui Pharmaceuticals, Gastric & gastro-oesophageal junction cancer and the tag pipeline.